Liverpool scientists have found a way of identifying families at high risk of pancreatic cancer

NewsGuard 100/100 Score

Scientists at the University of Liverpool have found a way of identifying families at high risk of pancreatic cancer. The team has developed a novel means of testing for pancreatic cancer that will enable doctors to treat the killer disease at its earliest stages. They are also now able to show how the risk of cancer for these patients changes with age.

The Liverpool-based study group known as EUROPAC (European Registry Of Hereditary Pancreatitis And Familial Pancreatic Cancer), working in collaboration with a similar group in Germany, has shown that familial pancreatic cancer develops at an increasingly younger age as it is passed down generations - a phenomenon known as anticipation.

In the largest study of its kind, the team surveyed 600 families with a history of pancreatic cancer and identified a subgroup of over 80 families whose lifetime risk of developing the cancer was 50 per cent.

Dr Bill Greenhalf, from the University's Division of Surgery and Oncology, said: "Of those families with the highest incidence of pancreatic cancer, we found that members developed the disease at a younger age in each generation. As well as giving important clues about the nature of the disease, this allows a more accurate estimate of the risk an individual faces of developing cancer in the short term so we can treat the cancer as soon as possible."

The team led by Dr Greenhalf has developed a novel method of analysing pancreatic juice, taken from patients in families with a history of pancreatic cancer. By analysing DNA scientists are able to identify specific genetic mutations that indicate the chances of a patient developing the disease in the short term, ranging from a 0.1% chance to a 90% certainty.

Dr Greenhalf added: "Our research has provided strong evidence that anticipation and pancreatic juice analysis are the most effective means of screening for pancreatic cancer in families with a history of the disease. We intend to carry out further trials of these techniques and hope the results encourage more widespread adoption of these screening methods."

http://www.liv.ac.uk/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases